|China Biologic Products Inc -- USA Stock|| |
USD 80.32 0.74 0.91%
Ms. Zhijing Liu is Corporationrationrate Vice President of China Biologic Products, Inc. She oversees plasma quality management, plasma resource development and matters related to regulatory affairs. From January 2010 to May 2011, Ms. Liu held various management positions at our Company, including being the Chief Representative of the Companys Beijing office. From May 2011 to August 2012, Ms. Liu was our Director of the Regulatory Affairs and Administration
Age: 62 VP Since 2012
(86) 10 6598 3222 www.chinabiologic.com
Liu has more than 30 years of experience in China?s pharmaceutical industry, holding various senior marketing, human resource, consulting and general management positions with various pharmaceutical organizations. Prior to joining us, Ms. Liu was general manager of Zhongbang Medical Technology Company, an affiliate of Hospital Management Institute of Ministry of Health.
The company has return on total asset (ROA)
of 13.27 %
which means that it generated profit of $13.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 22.21 %
meaning that it created $22.21 on every $100 dollars invested by stockholders.
The company currently holds 14.47 M in liabilities with Debt to Equity (D/E) ratio of 2.3 implying the company greatly relies on financing operations through barroing. China Biologic Products Inc has Current Ratio of 5.11 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasmabased biopharmaceutical solutions to hospitals and inoculation centers in the People?s Republic of China. China Biologic Products Inc (CBPO) is traded on NASDAQ in USA. It is located in CHINA and employs 1,667 people. China Biologic is listed under Pharmaceutical Products category by Fama And French industry classification.